$SRTA

Heyburn William A. sold $186K of SRTA

Heyburn William A. (Co-CEO and CFO) sold 31,671 shares of Strata Critical Medical, Inc. (SRTA) at $5.87 ($0.19M total) on 2026-06-08.

Original reporting
SEC EDGAR · Heyburn William A.
Published Jun 10, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SRTA
Bearish
medium confidence
Mentioned
$SRTA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRTABearishLow
01

Why it matters

Top executive selling can influence short-term sentiment, but traders typically need corroborating fundamental news (earnings, guidance, trial/regulatory updates) to reprice the stock materially.

02

Market read

Provides a fresh, primary-source datapoint of insider selling at a specific price and date; useful for sentiment/positioning checks rather than a standalone catalyst.

03

What to watch

The filing does not state intent, liquidity needs, or whether other insiders/large holders are buying; without follow-on transactions, signal-to-noise is low.

Relevance 4/10Novelty 8/10Timing: filed 2026-06-10 (sale dated 2026-06-08)

Background

The article is an SEC Form 4 insider transaction disclosure for Strata Critical Medical, Inc.

Company-level read

Ticker impact

$SRTABearishMedium confidence
Context

Strata Critical Medical disclosed a Form 4 showing Co-CEO/CFO Heyburn William A sold 31,671 shares at $5.87 on 2026-06-08.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The article is a primary-source insider transaction (Form 4) with a defined sale size and price, but it provides no new business, guidance, or regulatory/contract catalyst.

Market effects

Minimal; this is company-specific insider activity with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

A non-10b5-1 pre-arranged plan is not used here, but insider sales can be driven by diversification/taxes rather than bearish fundamentals.

Key entities

  • Strata Critical Medical, Inc.

    Company whose insider transaction was disclosed on SEC Form 4.

  • Heyburn William A.

    Co-CEO and CFO who sold 31,671 shares at $5.87 on 2026-06-08.

Related articles

$SRTAMed

Strata Critical Medical, Inc. (SRTA): Results of Operations and Financial Condition

Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 srta-earningreleasexq22026.htm EX-99.1 Document Exhibit 99.1 August 4, 2026 Strata Critical Medical Announces Second Quarter 2026 Results • Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 • Clinical revenue increased 22.6% sequentially in Q2 2026; Exc